Apyx Medical Corp

NASDAQ:APYXUnited States

Nov 8, 2024

Show headlines and story abstract

• Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering, from 7:05AM ET on Friday Nov 08, 2024 by Dow Jones

  7:05AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: APYX
  
  Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering
  
  CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion(R), today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company's common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company's common stock at a purchase price of $1.179 per pre-funded warrant (which represents the per share offering price for common stock less the exercise price per share for each pre-funded warrant of $0.001). The gross proceeds to Apyx Medical from the offering were approximately $7,000,000, before deducting offering expenses payable by the Company. The offering closed on November 8, 2024.
  

• -- Earnings Flash (APYX) APYX MEDICAL CORPORATION Posts Q3 Revenue $11.5M, from 7:02AM ET on Friday Nov 08, 2024 by MT Newswires

  7:02AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: APYX
  07:02 AM EST, 11/08/2024 (MT Newswires) -- ...

• Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook, from 7:00AM ET on Friday Nov 08, 2024 by Dow Jones

  7:00AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: APYX
  (Unaudited) December 31, 2023 ---------------------- --------------------- ASSETS Current assets: Cash and cash equivalents $ 28,013 $ 43,652 Trade accounts receivable, net of allowance of $750 and $608 13,036 14,023 Inventories, net of provision for obsolescence of $930 and $875 9,000 9,923 Prepaid expenses and other current assets 2,109 2,764 -------------- -------------- Total current assets 52,158 70,362 Property and equipment, net of accumulated depreciation and amortization of $3,889 and $3,522 1,905 1,915 Operating lease right-of-use assets 4,820 5,162 Finance lease right-of-use assets 53 69 Other assets 1,785 1,732 -------------- -------------- Total assets $ 60,721 $ 79,240 ============== ============== LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 1,914 $ 2,712 Accrued expenses and other current liabilities 7,291 9,661 Current portion of operating lease liabilities 330 347 Current portion of finance lease liabilities 20 20 -------------- -------------- Total current liabilities 9,555 12,740 Long-term debt, net of debt discounts and issuance costs 33,853 33,185 Long-term operating lease liabilities 4,606 4,896 Long-term finance lease liabilities 38 53 Long-term contract liabilities 1,271 1,246 Other liabilities 201 198 -------------- -------------- Total liabilities 49,524 52,318 EQUITY Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of September 30, 2024 and December 31, 2023 -- -- Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,926 issued and outstanding as of September 30, 2024, and 34,643,888 issued and outstanding as of December 31, 2023 35 35 Additional paid-in capital 84,289 81,114 Accumulated deficit (73,283) (54,448) -------------- -------------- Total stockholders' equity 11,041 26,701 Non-controlling interest 156 221 -------------- -------------- Total equity 11,197 26,922 -------------- -------------- Total liabilities and equity $ 60,721 $ 79,240 ============== ==============
  

• *DJ Apyx Medical 3Q Loss/Shr 14c >APYX, from 7:00AM ET on Friday Nov 08, 2024 by Dow Jones

  7:00AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: APYX